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ABSTRACT 
Objectives Global vaccination policy advocates for identifying and targeting groups who are 
underserved by vaccination to increase equity and uptake. We investigated whether birth weight and 
other factors are determinants of neonatal BCG vaccination in order to identify infants underserved 
by vaccination.  
Methods We used logistic regression to calculate adjusted ORs (AORs) for the association between 
birth weight (categorised as non-low birth weight (NLBW) (≥2.50 kg) and low birth weight (LBW) (2–
2.49 kg, 1.50–1.99 kg and <1.50 kg)) and non-vaccination with BCG at the end of the neonatal period 
(0–27 days). We assessed whether this association varied by place of delivery and infant illness. We 
calculated how BCG timing and uptake would improve by ensuring the vaccination of all facility-born 
infants prior to discharge.  
Results There was a strong dose–response relationship between LBW and not receiving BCG in the 
neonatal period (p-trend<0.0001). Infants weighing 1.50– 1.99 kg had odds of non-vaccination 1.6 
times (AOR 1.64; 95% CI 1.30 to 2.08), and those weighing <1.50 kg 2.4 times (AOR 2.42; 95% CI 1.50 
to 3.88) those of NLBW infants. Other determinants included place of delivery, distance to the health 
facility and socioeconomic status. Neither place of delivery nor infant illness modified the association 
between birth weight and vaccination (p-interaction all >0.19). Facility-born infants were vaccinated 
at a mean of 6 days, suggesting that they were not vaccinated in the facility at birth but were referred 
for vaccination. 
Conclusions LBW is a risk factor for neonatal undervaccination, even for facility-born infants. Ensuring 
vaccination at facility births would substantively improve timing and equitable BCG vaccination. 
  
  
What is already known on this topic? 
▸  Delayed BCG vaccination was associated with low birth weight (LBW) among primarily facility-born 
infants in urban slums in Kenya. 
▸  Undernourishment (caused by LBW, illness and feeding practices) was also associated with delayed 
BCG vaccination in urban Nigeria. 
What this study adds? 
▸  This large, generalisable prospective population-based cohort study in rural Ghana demonstrates 
lower compliance with the BCG vaccination schedule among LBW compared with non-LBW infants. 
▸  LBW is a strong determinant of neonatal BCG vaccination, with a dose–response relationship 
between birth weight and vaccination. 
▸  The association persists even for facility-born LBW infants, suggesting a lack of compliance with 
policy to vaccinate prior to discharge from the facility. 
INTRODUCTION 
Approximately 3 in 10 deaths among children aged 1–59 months are vaccine preventable,1 and 1 in 5 
infants is not fully vaccinated by age 52 weeks. Substantive socio-demographic inequities in 
vaccination remain.2 Many infants are vaccinated late.3 4 The latest global vaccination policy 
highlights the need to identify and target those underserved by vaccination in order to increase equity 
and uptake.2 Using data from a large prospective population based trial of neonatal vitamin A 
supplementation in Kintampo in rural Ghana (Neovita), we previously reported that low birthweight 
(LBW) infants are more likely to be delayed in their DTP1 and DTP3 vaccination.5 For postneonatal 
vaccines, the onus is on the caretaker to bring the infant for vaccination at scheduled times. Any 
vaccination delay may be partly due to caretaker hesitancy to bring infants for vaccination, possibly 
due to their fragility or illness.6 This may not be the case for neonatal vaccinations as the large 
proportion of facility-born infants automatically have opportunities for vaccination. Consequently, 
vaccine determinants may differ in these periods. In an effort to identify further those underserved 
by vaccination, we investigated birth weight and other factors as determinants of neonatal 
vaccination. 
In countries with a high prevalence of tuberculosis, the WHO recommends ‘BCG be given to all healthy 
neonates, or as soon as possible after birth’.7 In addition to BCG, in Ghana, a birth dose of polio (OPVB) 
is recommended at a maximum age of 2 weeks8 as part of a four-dose schedule. Hepatitis B is not 
recommended in the schedule. The WHO recommends BCG vaccination by intradermal injection to 
the arm,7 whereas OPVB is given orally.9 We selected BCG as an indicator for neonatal vaccination 
due to its longer recommended window for administration (throughout the neonatal period) and on 
the basis that any hesitancy relating to the vaccination of fragile infants would be more evident for 
injected vaccines. 
 LBW is not a contraindication to BCG vaccination.7 The WHO advises that infants should receive all 
due vaccines prior to discharge from health facilities.10 Therefore, infants born in health facilities 
should be vaccinated prior to discharge home. 
Infant illness has been cited as a reason for non-vaccination by both caregivers and vaccine providers.6 
Given this and the opportunities for vaccination associated with being born in a facility, as secondary 
objectives we investigated whether the association between birth weight and neonatal BCG 
vaccination varied by place of delivery and infant illness. 
MATERIALS AND METHODS 
Neovita was undertaken at the Kintampo Health Research Centre (KHRC) in rural Ghana. Trial methods 
have been described in detail elsewhere.11 12 
In Ghana, neonatal vaccines are given either at the health facility following delivery or at child health 
clinics in health facilities or community health planning system (CHPS) compounds in the community. 
Monthly mobile outreach clinics target areas lacking health facilities or CHPS compounds. Following 
vaccination, the vaccine provider records (on a vaccination card or, less commonly, in the mother’s 
antenatal card) the administrated vaccine, the batch number, date and clinic name. 
Infants who were up to three days of age at screening, who could suckle or feed and who were staying 
in the study area for at least six months after enrolment were included in the trial. 
Trained field workers used a prospective surveillance system (that monitored registered women aged 
15–49 years for pregnancies and deliveries) to ascertain all births in the study area between August 
2010 and November 2011. They enrolled eligible infants of consenting mothers in the trial and 
weighed them using calibrated electronic (38%) or spring (62%) scales. They recorded birth weights to 
the nearest 0.1 kg (electronic scales) or 0.2 kg (spring scales). All but five infants (0.2%) were weighed 
within 72 hours of delivery. At enrolment, field workers collected data on infant, maternal and 
household characteristics. Data on vaccination status (written record and maternal recall) were 
collected at monthly follow-up visits. 
Infants were categorised as (1) vaccinated, known vaccination date (if they had a plausible vaccination 
date on their vaccination card); (2) vaccinated, unknown vaccination date (if they had an unknown or 
implausible date on their card); and (3) unvaccinated (if either (a) their card was viewed and had no 
evidence of vaccination or (b) their card was not viewed (possibly because they did not have a card) 
but their caretaker consistently reported that they had never been vaccinated). In addition, infants 
whose card was never viewed and whose mothers reported they were vaccinated, but did not report 
which vaccine they received, were categorised as vaccination status unknown as were those infants 
never seen in follow-up, with no information on their vaccination status. 
We categorised infants as either non-low birth weight (NLBW) (weighing ≥2.50 kg) or LBW (2.00–2.49 
kg, 1.50– 1.99 kg and <1.50 kg). Neonatal illness was a health facility admission in the neonatal period 
(0–27 days of age). 
Infants with known vaccination status, in follow-up at the end of the neonatal period and having 
complete covariate data were eligible for inclusion in the analyses. 
Analytical methods 
We conducted all analyses using STATA V.14.1 (StataCorp, 2015). As neonatal BCG vaccination is a 
frequent event, we calculated adjusted ORs (AORs) for the less frequent outcome of non-vaccination 
(rather than for vaccination) using multivariable logistic regression. The resulting AORs for this less 
frequent outcome thus approximated more closely to risk or rate ratios. Model building was informed 
by a hierarchical framework5 of the determinants of vaccination identified a priori.3 4 13 14 We 
initially fit a model comprising distal determinants (religion, ethnicity, socioeconomic status (SES), 
maternal occupation, maternal education, vaccine due in wet season, infant sex); then added 
intermediate determinants (maternal age/family size, maternal illness in the year before delivery, 
distance to the nearest health facility, place of delivery, multiple birth), followed by birth weight and, 
finally, infant illness, a possible mediator of the association between birth weight and vaccination. We 
used likelihood ratio tests and 95% CIs to assess statistical associations between each explanatory 
variable and vaccination. 
We fitted interaction terms of birth weight and (1) place of delivery, and (2) neonatal illness to the 
final model to assess whether either of these modified the association between birth weight and 
vaccination. 
For all infants, irrespective of place of birth, we calculated BCG uptake rates at the end of the neonatal 
period and at 8, 12 and 52 weeks of age, stratified by birth weight, to examine variation by time since 
the due date. To assess how ensuring vaccination of facility-born infants prior to discharge would 
affect vaccination, we calculated ‘theoretical’ proportions vaccinated by assigning these infants as 
vaccinated in the neonatal period. We calculated the proportional increase in vaccination by dividing 
the theoretical proportion by the actual proportion for each time period. 
RESULTS 
Of 22 955 infants enrolled in Neovita, 22 217 (96.8%) were included in the analyses. Among 738 
excluded, 362 were BCG vaccination status unknown, 242 were BCG vaccinated with an unknown 
date, 88 were lost to follow-up in the neonatal period and 46 were missing covariate data. Of those 
excluded, 275 died in the neonatal period. Table 1 shows that excluded infants were more likely to 
have LBW, to live further from a health facility, to be a multiple birth and to have poorer mothers. 
Infants were BCG vaccinated at a median of 8 days; 77% were vaccinated by the end of the neonatal 
period. Uptake decreased with declining birth weight and was lowest (60%) among infants weighing 
<1.50 kg. There was a strong dose– response relationship between LBW and the odds of non-
vaccination in the neonatal period (p-trend<0.0001) after adjustment for other variables (table 2). 
Infants weighing 1.50– 1.99 kg (AOR 1.64; 95% CI 1.30 to 2.08) and those weighing <1.50 kg (AOR 2.42; 
95% CI 1.50 to 3.88) had odds of non-vaccination 1.6 times and 2.4 times those of NLBW infants. 
Not being born in a health facility (compared with being born in a health facility), living ≥5 km from 
the nearest health facility (compared with living within 1 km of a health facility) and being in the lowest 
quintile of SES (compared with the highest) were all strongly associated with not receiving BCG in the 
neonatal period (table 2). Almost 40% of home-born infants were BCG unvaccinated, and their odds 
of non-vaccination were 1.82 times those of facility-born infants (AOR 1.82; 95% CI 1.69 to 1.98; 
p≤0.0001). Infants living >5 km from a health facility had odds of non-vaccination 1.37 times those of 
infants living within 1 km (AOR 1.37; 95% CI 1.25 to 1.49; p≤0.0001) even after adjusting for place of 
birth and other factors. A strong dose–response relationship was observed between SES and neonatal 
BCG vaccination (p-trend <0.0001), with infants from the poorest quintile of SES having odds of 
Table 1 Baseline characteristics of infants included in the analyses of determinants of neonatal BCG 
vaccination 
  Excluded  Included 
Variable  Total=738  Total=22 217 
Distal determinants   
Religion of head of 
household 
  
Christian  471 (63.8)  15 508 (69.8) 
Muslim  201 (27.2)  5310 (23.9) 
None/traditional/other  66 (8.9)  1399 (6.3) 
Ethnicity   
Akan  317 (43.0)  10 376 (46.7) 
Non-Akan  421 (57.0)  11 841 (53.3) 
Socioeconomic status   
1 (poorest)  185 (25.1)  4325 (19.5) 
2  174 (23.6)  4376 (19.7) 
3  150 (20.3)  4433 (20.0) 
4  125 (16.9)  4519 (20.3) 
5 (richest)  103 (14.0)  4564 (20.5) 
Missing values  1 (0.1)   
Maternal occupation   
Government/private/other  31 (4.2)  1194 (5.4) 
Self-employed  232 (31.4)  8714 (39.2) 
Farming  251 (34.0)  6420 (28.9) 
Does not work  224 (30.4)  5889 (26.5) 
Maternal education    
None  264 (35.8) 6863 (30.9) 
Primary school  138 (18.7)  4098 (18.5) 
Secondary/tertiary  322 (43.6)  11 256 (50.7) 
Missing values  14 (1.9)   
Vaccine due in wet season  461 (62.5)  14 494 (65.2) 
Sex, female  340 (46.1)  10 966 (49.4) 
Intermediate determinants   
Maternal age 
(years)/family size 
  
<20  114 (15.4)  2531 (11.3) 
20–29; 1–3 children  263 (35.6)  7815 (35.2) 
20–29; ≥4 children  120 (16.3)  3843 (17.3) 
≥30; 1–3 children  29 (3.9)  1108 (5.0) 
≥30; ≥4 children  182 (24.7)  6920 (31.2) 
Missing values  30 (4.1)   
Maternal illness in year 
before delivery 
 32 (4.3)  1091 (4.9) 
Distance (km)   
<1.00  409 (55.5) 13 471 (60.6) 
1.00-4.99   152 (20.6)  5133 (23.1) 
≥5.00  174 (23.6)  3613 (16.3) 
Missing values  2 (0.3)   
Facility delivery  517 (70.1)  17 064 (76.8) 
Multiple birth  52 (7.1)  795 (3.6) 
Proximal variables   
Birth weight (kg)   
≥2.5  520 (70.5)  18 841 (84.8) 
2.00-2.49   121 (16.4)  2910 (13.1) 
1.50-1.99  59 (8.0)  385 (1.7) 
<1.50  36 (4.8)  81 (0.4) 
Missing values  2 (0.3)   
Mediating variables    
Neonatal illness  31 (4.2)  426 (1.9) 
 
non-vaccination 2.7 times greater than those from the wealthiest quintile (AOR 2.69; 95% CI 2.34 to 
3.08) even after adjustment for all other explanatory variables. 
Being a farmer or unemployed (compared with being self-employed), having primary school education 
or no education (compared with secondary/tertiary education) and being aged <20 years of age 
(compared with being aged ≥30 with four or more children) were associated with an increased odds 
of non-vaccination in the final model. Conversely, female infants had lower odds of non-vaccination 
(table 2). 
There was little variation in the effect size for the distal factors, after adjustment for intermediate and 
proximal mediating variables, and in the effect size for intermediate-level factors, after adjustment 
for birth weight. Illness did not appear to mediate the effect of birth weight or any other determinants 
of vaccination (table 2). 
There was little evidence that either place of delivery or infant illness modified the association 
between birth weight and vaccination (p value for interaction all >0.2). 
Additional analyses of the vaccination of facility-born infants 
As a post hoc analysis, we further explored the vaccination of facility-born infants. We analysed their 
age at vaccination and analysed their determinants of vaccination. 
Facility-born infants were vaccinated at a median age of 6 days (IQR 17). The effect estimates for the 
determinants of vaccination were very similar to those for the entire study population. The most 
important effect was for infants living >5 km from a health facility (AOR 1.60; 95% CI 1.41 to 1.81) 
(table 2). 
Impact of vaccinating all facility-born infants before discharge 
Overall BCG uptake was 77.1% (95% CI 76.5 to 77.6) by the end of the neonatal period, 91.8% (95% CI 
91.4 to 92.1) by 8 weeks of age, 95.9% (95% CI 95.6 to 96.1) by 12 weeks of age and 98.7% (95% CI 
98.5 to 98.8) by 52 weeks of age (table 3). At each of these time points, uptake declined with 
decreasing birth weight, although there was little difference at age 52 weeks (table 3). We calculated 
that 91.0% (95% CI 90.6 to 91.3) of all infants, 91.2% (95% CI 87.9 to 93.6) of infants weighing 1.50–
1.99 kg and 88.9% (95% CI 79.9 to 94.1) of infants weighing <1.50 kg may have been vaccinated in the 
neonatal period if all facility-born infants were vaccinated prior to discharge. This represented a 
respective 18%, 31% and 47% increase in vaccine uptake by the end of the neonatal period. Similar 
smaller gains in vaccine uptake would have occurred for the other categories of birth weight (table 3). 
DISCUSSION 
Our analyses indicate that LBW infants are at high risk of missing BCG vaccination in the neonatal 
period. There appears to be a dose–response relationship between vaccination and birth weight; 
vaccination declines with decreasing birth weight, regardless of place of birth. 
We excluded sicker weaker infants who were unable to feed at enrolment, as well as those who died 
during the neonatal period. The LBW infants included in our analyses were probably well, and illness 
was probably not a contraindication to vaccination. Our finding that neonatal illness did not appear to 
mediate the association between birth weight and vaccination, overall or when stratified by place of 
delivery, supports this. LBW is not a contraindication to vaccination, and LBW infants are 
recommended to be vaccinated at the same chronological age as NLBW infants;15 however, our 
results indicate that this recommendation is not being optimally adhered to in Ghana. We identified 
a number of additional determinants of neonatal BCG vaccination, including place of delivery, distance 
to health facility, SES, and maternal education, occupation and age. 
  
 Table 2 Determinants of non-vaccination with BCG in the neonatal period 
 
Not 
vaccinat
ed/ total 
Proporti
on not 
vaccinat
ed (95% 
CI) 
Unadjust
ed ORs 
OR (95% 
CI) 
(p value) 
Adjusted 
for distal 
determinan
ts 
AOR (95% 
CI) 
(p value) 
Adjusted for 
distal and 
intermedi
ate 
determina
nts 
AOR (95% 
CI) 
(p value) 
Adjusted 
for distal, 
intermediat
e and 
proximal 
determinan
ts (final 
model) 
AOR (95% 
CI) 
(p value) 
Final 
model 
adjusted 
for 
mediating 
effects of 
infant 
illness 
AOR 
(95% CI) 
(p value) 
Final 
model; 
among 
infants 
born in 
a health 
facility 
AOR 
(95% 
CI) 
(p 
value) 
Distal variables 
Religion of head of 
household 
 Christian  
3387/15 508 
21.8 (21.2–
22.5) Ref Ref Ref Ref Ref Ref 
 Muslim  1310/5310 24.7 (23.5–
25.8) 
1.17 
(1.09–
1.26) 
1.04 
(0.95–
1.13) 
1.01 (0.93–
1.10) 
1.01 
(0.93–
1.11) 
1.01 
(0.93–
1.11) 
1.00 
(0.89–
1.11) 
None/traditional/  392/1399 
other 
28.0 (25.7–
30.4) 
1.39 
(1.23–
1.58) 
(<0.000
1) 
0.96 
(0.85–
1.09) 
(0.5416) 
0.90 
(0.79–
1.03) 
(0.243
8) 
0.90 
(0.79–
1.03) 
(0.2445) 
0.90 
(0.79–
1.03) 
(0.2439) 
0.86 
(0.72–
1.03) 
(0.244
0) 
Ethnicity 
 Akan  
1891/10 376 
18.2 (17.5–
19.0) Ref Ref Ref Ref Ref Ref 
 Non-Akan  3198/11 841 27.0 (26.2–
27.8) 
0.60 
(0.56–
0.64) 
(<0.000
1) 
0.91 
(0.84–
0.99) 
(0.0320) 
0.94 (0.86–
1.02) 
(0.1381) 
0.93 
(0.86–
1.02) 
(0.1112) 
0.93 
(0.86–
1.02) 
(0.1099) 
0.96 
(0.87–
1.06) 
(0.409
2) 
Socioeconomic status 
 1 (poorest)  
1618/4325 
37.4 (36.0–
38.9) 
5.19 
(4.63–
5.82) 
3.90 
(3.42–
4.44) 
2.70 (2.35–
3.10) 
2.69 
(2.34–
3.08) 
2.68 
(2.33–
3.08) 
2.98 
(2.53–
3.50) 
2 1271/4376 29.0 (27.7–
30.4) 
3.56 
(3.17–
3.99) 
2.91 
(2.57–
3.29) 
2.33 (2.05–
2.65) 
2.32 
(2.04–
2.64) 
2.32 
(2.04–
2.64) 
2.34 
(2.03–
2.71) 
3 1020/4433 23.0 (21.8–
24.3) 
2.60 
(2.31–
2.92) 
2.27 
(2.01–
2.57) 
1.98 (1.75–
2.24) 
1.98 
(1.74–
2.24) 
1.98 
(1.74–
2.24) 
1.98 
(1.72–
2.26) 
4 709/4519 15.7 (14.7–
16.8) 
1.62 
(1.43–
1.83) 
1.50 
(1.32–
1.70) 
1.42 (1.25–
1.61) 
1.41 
(1.24–
1.60) 
1.41 
(1.24–
1.60) 
1.47 
(1.28–
1.68) 
5 (richest) 471/4564 10.3 (9.5–
11.2) 
Ref 
(<0.000
1) 
Ref 
(<0.0001) 
Ref 
(<0.0001) 
Ref 
(<0.0001) 
Ref 
(<0.0001)
* 
Ref 
(<0.00
01) 
Maternal occupation 
 
 
 
      
Government/ private/other 158/1194 
13.2 (11.4–
15.3) 
0.73 
(0.61–
0.87) 
0.89 
(0.75–
1.07) 
0.92 (0.76–
1.10) 
0.91 
(0.76–
1.09) 
0.91 
(0.76–
1.10) 
0.92 
(0.75–
1.12) 
Self-employed 1500/8714 17.2 (16.4–
18.0) 
Ref Ref Ref Ref Ref 
Ref 
Farming 2082/6420 32.4 (31.3–
33.6) 
2.31 
(2.14–
2.49) 
1.33 
(1.22–
1.46) 
1.21 (1.11–
1.33) 
1.21 
(1.11–
1.33) 
1.21 
(1.11–
1.33) 
1.24 
(1.11–
1.39) 
Does not work 1349/5889 22.9 (21.9–
24.0) 
1.43 
(1.32–
1.55) 
(<0.000
1) 
1.19 
(1.09–
1.30) 
(<0.0001) 
1.13 (1.03–
1.24) 
(0.0001) 
1.13 
(1.03–
1.24) 
(0.0001) 
1.13 
(1.03–
1.24) 
(0.0001) 
1.18 
(1.06–
1.32) 
(0.000
1) 
Maternal education 
 
 
      
 
None 2032/6863 
29.6 (28.5–
30.7) 
1.95 
(1.81–
2.09) 
1.13 
(1.03–
1.24) 
1.15 
(1.05–
1.26) 
1.15 
(1.05–
1.27) 
1.15 
(1.05–
1.27) 
1.13 
(1.01–
1.27)) 
Primary school 1057/4098 25.8 (24.5–
27.2) 
1.61 
(1.48–
1.75) 
1.18 
(1.08–
1.29) 
1.17 (1.07–
1.28) 
1.17 
(1.06–
1.28) 
1.17 
(1.06–
1.28) 
1.17 
(1.05–
1.31) 
Secondary/tertiary 2000/11 256 17.8 (17.1–
18.5) 
Ref 
(<0.000
1) 
Ref 
(0.0013) 
Ref 
(0.0013) 
Ref 
(0.0015) 
Ref 
(0.0015) 
REF0.
0138 
Vaccine due in wet season 
        
 
Yes  
3272/14 494 
22.6 (21.9–
23.3) Ref Ref Ref Ref Ref 
Ref 
 
No 1817/7723 23.5 (22.6–
24.5) 
1.06 
(0.99–
1.13) 
(0.1082) 
1.04 
(0.97–
1.11) 
(0.2274) 
1.04 (0.97–
1.12) 
(0.2284) 
1.04 
(0.97–
1.12) 
(0.2353) 
1.04 
(0.97–
1.12) 
(0.2402) 
1.05 
(0.97–
1.15) 
0.2121 
Sex 
   
 
       
Male 2701/11 251 24.0 (23.2–
24.8) Ref Ref Ref Ref Ref Ref 
 Female  2388/10 966 21.8 (21.0–
22.6) 
0.88 
(0.83–
0.94) 
(0.0001) 
0.87 
(0.82–
0,93) 
(<0.0001) 
0.86 (0.80–
0.92) 
(<0.0001) 
0.85 
(0.80–
0.91) 
(<0.0001) 
0.85 
(0.80–
0.91) 
(<0.0001) 
0.83 
(0.77–
0.90) 
(<0.00
01) 
Intermediate variables 
 
 
        
Maternal age (years)/family 
size 
        
<20                     650/2531 25.7 (24.0–
27.4) 
1.10 
(98.8–
1.22) 
 1.22 (1.07–
1.39) 
1.19 
(1.04–
1.35) 
1.19 
(1.04–
1.35) 
1.27 
(1.09–
1.48) 
 
20–29; 1–3        
children 
1601/7815 20.5 (19.6–
21.4) 
1.10 
(98.8–
1.22) 
 1.22 (1.07–
1.39) 
1.19 
(1.04–1.35 
1.19 
(1.04–
1.35) 
1.27 
(1.09–
1.48) 
20–29; ≥4 
children 
1008/3843 26.2 (24.9–
27.6) 
1.13 
(1.03–
1.24) 
 1.11 (1.01–
1.22) 
1.11 
(1.10–
1.22) 
1.11 
(1.01–
1.22) 
1.14 
(1.01–
1.29) 
≥30; 1–3 
children 
173/1108 15.6 (13.6–
17.9) 
0.59 
(0.50–
0.70) 
 0.93 (0.77–
1.11) 
0.92 
(0.76–
1.10) 
0.92 
(0.76–
1.10) 
0.97 
(0.78–
1.19) 
≥30; ≥4 children 1657/6920 23.9 (23.0–
25.0) 
Ref 
(<0.000
1) 
 Ref 
(0.0080) 
Ref 
(0.0186) 
Ref 
(0.0191) 
Ref 
(0.019
4) 
Maternal illness in year 
before delivery 
        
No 
 
4840/21 126  22.9 (22.3–
23.5 
Ref  Ref Ref Ref Ref 
Yes 249/1091 22.8 (20.4–
25.4) 
1.00 
(0.86–
1.15) 
(0.9468) 
 0.94 (0.80–
1.09) 
(0.3866) 
0.93 
(0.80–
1.08) 
(0.3568) 
0.93 
(0.80–
1.08) 
(0.3545) 
0.92 
(0.76–
1.11) 
(0.376
4) 
Distance from health 
facility (km) 
        
<1.00 2570/13 471 19.1 (18.4–
19.8) 
Ref Ref Ref Ref Ref Ref 
1.00–4.99 1146/5133 22.3 (21.2–
23.5) 
1.22 
(1.13–
1.32) 
 1.06 (0.98–
1.16)  
1.06 
(0.98–
1.15)  
1.06 
(0.98–
1.15)  
1.06 
(0.96–
1.17) 
≥5.00 1373/3613 38.0 (36.4–
39.6) 
2.60 
(2.40–
2.82) 
(<0.000
1) 
 1.37 (1.25–
1.50) 
(<0.0001) 
1.37 
(1.25–
1.49) 
(<0.0001) 
1.37 
(1.25–
1.49) 
(<0.0001) 
1.60 
(1.41–
1.81) 
(<0.00
01) 
Place of birth         
Facility 3079/17 064 18.0 (17.5–
18.6) 
Ref  Ref Ref Ref  
39.0 (37.7–40.3) 2010/5153 39.0 (37.7–
40.3) 
2.90 
(2.71–
3.11) 
(<0.000
1) 
 1.83 (1.69–
1.98) 
(<0.0001) 
1.82 
(1.69–
1.98) 
(<0.0001) 
1.83 
(1.69–
1.98) 
(<0.0001) 
 
Multiple birth         
No 4898/21 422 22.9 (22.3–
23.4) 
Ref  Ref Ref Ref Ref 
Yes 191/795 24.0 (21.2–
27.1) 
1.07 
(0.90–
1.26) 
(0.4468) 
 1.08 (0.91–
1.29) 
(0.3692) 
0.93 
(0.78–
1.13) 
(0.4742) 
0.93 
(0.78–
1.13) 
(0.4747) 
1.00 
(0.81–
1.23) 
(0.988
9) 
Proximal variables         
Birth weight (kg)         
≥2.5 4204/18 841 22.3 (21.7–
22.9) 
Ref   Ref Ref Ref 
2.00–2.49 737/2910 25.3 (23.8–
26.9)  
1.18 
(1.08–
1.29)  
  1.08 
(0.98–
1.19)  
1.08 
(0.98–
1.19) 
1.12 
(0.99–
1.27) 
1.50–1.99 116/385 30.1 (25.7–
34.9) 
1.50 
(1.20–
1.87) 
  1.64 
(1.30–
2.08) 
1.64 
(1.30–
2.08) 
1.69 
(1.28–
2.22) 
<1.50 32/81 39.5 (29.4–
50.6) 
2.27 
(1.45–
3.55) 
(<0.000
1) 
  2.41 
(1.50–
3.88)) 
(<0.0001) 
2.42 
(1.51–
3.89) 
(<0.0001)
* 
2.29 
(1.35–
3.90 
(0.000
1) 
Mediating variable         
Neonatal illness         
No 5009/21 791 23.0 (22.4–
23.5) 
Ref    Ref Ref 
Yes 80/426 18.8 (15.3–
22.8) 
0.77 
(0.61–
0.99) 
(0.0363) 
   0.91 
(0.71–
1.17) 
(0.4627) 
0.89 
(0.66–
1.20) 
(0.454
2) 
 
*p trend ≤0.0001.  
 
 
 
 
Table 3 BCG uptake rates at 4, 8, 12 and 52 weeks of age by birth weight and rates that could be 
achieved if all those born in a facility had been vaccinated prior to discharge from the facility 
BCG uptake rates    
Birth weight (kg) Actual Theoretical % increase in 
vaccine uptake 
Age 4 weeks 
2.5 
77.7 (77.1–78.3) 91.2 (90.8–91.6) 17.4 
2.49 
74.7 (73.1–76.2) 89.4 (88.2–90.5) 19.7 
1.99 69.9 (65.1–74.3) 91.2 (87.9–93.6) 30.5 
<1.50 60.5 (49.4–70.6) 88.9 (79.9–94.1) 46.9 
Overall 77.1 (76.5–77.6) 91.0 (90.6–91.3) 18.0 
Age 8 weeks 
2.5 
92.1 (91.7–92.5) 96.7 (96.4–96.9) 5.0 
2.49 
90.4 (89.3–91.4) 95.7 (94.9–96.4) 5.9 
1.99 87.5 (83.8–90.5) 97.9 (95.9–99.0) 11.9 
<1.50 72.8 (62.1–81.4) 91.4 (82.9–95.8) 25.5 
Overall 91.8 (91.4–92.1) 96.5 (96.3–96.8) 5.1 
Age 12 weeks 
2.5 
96.1 (95.8–96.4) 98.2 (98.1–98.4) 2.2 
2.49 
95.1 (94.2–95.8) 97.8 (97.2–98.2) 2.8 
1.99 93.8 (90.9–95.8) 98.4 (96.6–99.3) 4.9 
<1.50 88.9 (79.9–94.1) 97.5 (90.6–99.4) 9.7 
Overall 95.9 (95.6–96.1) 98.2 (98.0–98.4) 2.4 
Age 52 weeks 
2.5 
98.8 (98.6–98.9) 99.5 (99.4–99.6) 0.1 
2.49 
98.1 (97.5–98.5) 99.1 (98.7–99.4) 1.0 
1.99 97.4 (95.2–98.6) 99.5 (97.9–99.9) 2.2 
<1.50 96.3 (89.1–98.8) 98.8 (91.7–99.8) 2.6 
Overall 98.7 (98.5–98.8) 99.4 (99.3–99.5) 0.7 
  
These were also identified as determinants in our analyses of postneonatal vaccination 5 and other 
analyses,16 and reflect broader inequities in access to care in our study population. 
In our study area, >20% of the 77% of facility-born infants were unvaccinated at the end of the 
neonatal period, demonstrating a lack of compliance with the routine schedule. This was double for 
infants weighing <1.5 kg at birth. 
Vaccination was even lower among home-born infants, suggesting parental delay in accessing 
vaccination services, or for those living far from a facility, the monthly scheduling of mobile outreach 
clinics. The fact that home-born LBW infants are even more delayed may reflect parental reluctance 
to bring fragile infants for vaccination, as previously documented in a review of unpublished surveys.6 
Facility-born infants were vaccinated at a median age of 6 days, suggesting that many are 
unvaccinated at discharge following delivery; they may instead be referred to the child health clinic 
for vaccination. This would explain why birth weight and other maternal and household factors remain 
as vaccine determinants among facility-born infants. If true, then this practice is allowing inequities in 
vaccination to persist. A single phial of BCG vaccinates 20 infants. Fear of wastage has previously been 
cited as a reason for missing opportunities for vaccination17 and may be a motivation for referring 
facility-born infants to the child health clinic for vaccination. 
Overall uptake of BCG vaccination at age 52 weeks was high; however, many infants were vaccinated 
late, including a higher proportion of LBW infants. BCG vaccination is known to have an important 
protective effect against tuberculous meningitis in the first five years of life.18 Timely vaccination is 
important so as not to prolong the risk of infection. Furthermore, timeliness of vaccination is 
increasingly recognised as an important indicator of the overall quality of vaccination programmes,19 
and our finding that LBW infants were less likely to be in compliance with the routine schedule 
highlights them as a group who are underserved by vaccination. The Global Vaccine Action Plan2 
advocates for identifying groups who are underserved by routine vaccination services so that they can 
be targeted for vaccination, and so that inequities in the delivery of the vaccination programme can 
be reduced. Ensuring vaccination of facility born infants prior to discharge would optimise compliance 
with the recommended schedule and the timeliness of BCG vaccination. 
Our finding of reduced vaccination of LBW infants is consistent with our previous finding of delayed 
postneonatal vaccination (with DTP1 and DTP3) of LBW infants.5 It also supports recent findings20 
from Nairobi, Kenya, that infants weighing <2.00 kg living in informal urban settlements took nine 
times longer to be vaccinated in the first 90 days of life than NLBW infants. The difference in the 
magnitude of the association between our study and the Kenyan study may be due to the exclusion 
of unvaccinated infants, the lower prevalence of LBW (6%), the higher proportion of facility-born 
infants (96%) and the higher proportion of private facility-born infants (67%) in the Kenyan study. 
Data from Guinea-Bissau21 also suggested lower BCG vaccination among LBW infants. As there was 
reportedly a national policy of delaying vaccination of LBW infants until they had gained weight or 
attended for DTP vaccination, these results are not generalisable to countries, such as Ghana, where 
no such policy exists. 
A study from Nigeria22 reported delayed vaccination of undernourished children. This study provides 
indirect evidence of the effect of birth weight, in addition to infant feeding and illness (the causes of 
undernourishment23) on BCG vaccination. 
Strengths 
Our study was strengthened by low loss to follow-up rates (<3%), by the population-based nature of 
the sample and by the collection of high-quality data on both birth weight and vaccination. 
Limitations 
We lacked qualitative data on the practices associated with vaccination following delivery, including 
the reasons why infants born in health facilities were not getting vaccinated, and why LBW infants 
born in health facilities were less likely to be vaccinated. This limits our understanding of the barriers 
to neonatal vaccination (among both facility-born and home-born infants) and to the vaccination of 
LBW infants. 
A large number of variables were included in our models, thus increasing the possibility of type 1 
errors. Due to small numbers, our study was underpowered to detect differences in analyses where 
birth weight was stratified by factors such as infant illness. Although we demonstrated that vaccinating 
all facility-born infants prior to discharge could substantively improve the timing and equity of delivery 
of BCG vaccination, this finding may not be generalisable to settings where most infants are born at 
home. 
CONCLUSIONS 
Our analyses indicate that LBW is a risk factor for not being vaccinated with BCG in the neonatal 
period, even for facility-born LBW infants. Efforts to improve neonatal vaccination, especially for LBW 
infants, are warranted, regardless of where they are born. For LBW infants born in facilities, 
vaccination prior to discharge is recommended. Qualitative studies to understand the reasons for non-
vaccination with BCG in the neonatal period are needed. In particular, studies are needed to 
understand why infants, including LBW infants born in health facilities, are not getting vaccinated. 
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